The Brown University Psychopharmacology Update
2016
A review and meta‐analysis of the effects of N‐methyl‐D‐aspartate (NMDA) receptor antagonists in treating major depression has confirmed that ketamine is the only such drug to date that has demonstrated antidepressant efficacy across multiple trials. Authors of the review stated, however, that the findings regarding ketamine should be viewed with caution because the beneficial effects are not...
PeerJ
2016
Jing J Wong, Owen O'Daly, Mitul A. Mehta et al.
Background. Ketamine has been reported to have efficacy as an antidepressant in several studies of treatment-resistant depression. In this study, we investigate whether an acute administration of ketamine leads to reductions in the functional connectivity of subgenual anterior cingulate cortex (sgACC) with other brain regions. Methods. Thirteen right-handed healthy male subjects underwent a 15...
Indian Journal of Psychological Medicine
2016
Mahesh Ramanna Gowda, Preethi Srinivasa, Prabha S Kumbar et al.
Ketamine, a primarily FDA-approved anaesthetic agent is also used as recreational drug. Based on preclinical findings and later the clinical observations it is noted to have rapid antidepressant effect due to its mechanisms related to NMDA antagonism. In spite of established evidence of ketamine being effective in depression with significant role in treatment resistant cases as well, there was...
Case Reports in Neurology
2016
Scott J Sherman, Miguel Estevez, Ari B Magill et al.
Ketamine is an FDA-approved drug with a known safety profile. Low-dose subanesthetic intravenous ketamine infusion treatment has led to long-term reduction of treatment-resistant depression and of chronic pain states. We report on low-dose subanesthetic intravenous ketamine infusion treatment in Parkinson's disease (PD) patients by 5 case studies and show a long-lasting therapeutic benefit to...
Neuropsychiatric Disease and Treatment
2016
Yuan-Yuan Lu, Chieh-Hsin Lin, Hsien-Yuan Lane
17 citations
Ketamine, a noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, has multiple clinical uses. On the other hand, ketamine abuse or recreational use has been gaining increasing attention. Induction of mania and psychotic symptoms has been reported in a patient receiving IV ketamine therapy for reflex sympathetic dystrophy. We here report a 26 year-old man who abused ketamine by...
Cell and tissue research
December 21, 2015
Malwina Lisek, T. Boczek, Bozena Ferenc et al.
Chronic N-methyl-D-aspartate receptor (NMDAR) antagonist treatment can provide valuable neurochemical and neuroanatomical models of experimental psychosis. One such antagonist, ketamine, with its short half-time and well-documented psychotomimetic action, has cognitive effects resembling various aspects of schizophrenia-like symptoms. In order to obtain insights into possible relationships...
Journal of Clinical Psychopharmacology
December 12, 2015
Yena Lee, Kahlood Syeda, Nadia A. Maruschak et al.
75 citations
Available evidence indicates that a single, low-dose administration of ketamine is a robust, rapid-onset intervention capable of mitigating depressive symptoms in adults with treatment-resistant mood disorders. Additional evidence also suggests that ketamine may offer antisuicide effects. Herein, we propose that the antidepressant effects reported with ketamine administration are mediated, in...
Neuropharmacology
December 1, 2015
Kinga Sałat, Agata Siwek, G. Starowicz et al.
Ketamine produces rapid and long-lasting antidepressant effects in patients. The involvement of ketamine metabolites in these actions has been proposed. The effects of ketamine and its metabolites norketamine and dehydronorketamine on ligand binding to 80 receptors, ion channels and transporters was investigated at a single concentration of 10 μM. The affinities of all three compounds were then...
Brain Connectivity
December 2015
Daniel Kleinloog, Serge A.r.b. Rombouts, Remco Zoethout et al.
This analysis examines the neuronal foundation of drug-induced psychomimetic symptoms by relating the severity of these symptoms to changes in functional connectivity for a range of different psychoactive compounds with varying degrees of psychomimetic effects. The repeated measures design included 323 resting-state functional magnetic resonance imaging time series and measures of subjective...
Schizophrenia Research
November 14, 2015
Ni Fan, Yayan Luo, Ke Xu et al.
Objective Exposing to NMDAR receptor antagonists, such as ketamine, produces schizophrenia-like symptoms in humans and deteriorates symptoms in schizophrenia patients. Meanwhile, schizophrenia is associated with alterations of cytokines in the immune system. This study aims to examine the serum TNF-α, IL-6 and IL-18 levels in chronic human ketamine users as compared to healthy subjects. The...